20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Ovid Therapeutics Inc (OVID) operates in the BIOTECHNOLOGY industry and is headquartered in New York, United States with about 23 employees. Its market capitalization is roughly $496 million. In the fiscal year ended 2025-12-31, OVID reported $7M in revenue and ($17M) in net income.
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States.
Interactive charts & full statements → Open the OVID valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $2M | $7M | $1M | $0M | $2M | $208M | $13M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | $2M | $7M | $1M | $0M | $2M | $208M | $13M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Margin % | 97.8% | 95.9% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — | — |
| Operating Income (EBIT) | ($58M) | ($42M) | ($62M) | ($59M) | ($56M) | $124M | ($81M) | ($61M) | ($53M) | ($65M) | ($23M) | ($13M) | $0M |
| Operating Margin % | -3686.7% | -585.2% | -10933.8% | -15122.7% | -3696.4% | 59.6% | -645.4% | — | — | — | — | — | — |
| Net Income | ($34M) | ($17M) | ($26M) | ($52M) | ($51M) | $123M | ($81M) | ($59M) | ($52M) | ($65M) | ($22M) | ($13M) | $0M |
| Net Margin % | -2178.9% | -240.1% | -4670.1% | -13351.8% | -3420.9% | 59.0% | -639.8% | — | — | — | — | — | — |
| EBITDA | ($36M) | ($17M) | ($58M) | ($57M) | ($54M) | $124M | ($81M) | ($61M) | ($53M) | ($65M) | ($22M) | ($13M) | $0M |
| Earnings Per Share (EPS) | $-0.49 | $-0.24 | $-0.37 | $-0.74 | $-0.73 | $1.80 | $-1.38 | $-1.51 | $-2.11 | $-3.35 | $-1.14 | $-0.67 | $-0.09 |
| Shares Outstanding (M) | 74M | 74M | 71M | 71M | 70M | 68M | 58M | 39M | 25M | 19M | 20M | 20M | 5M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1M | $0M | $1M | $0M | $6M | $0M | $0M | $0M |
| Gross Profit | $1M | $0M | $1M | $0M | $6M | $0M | $0M | $0M |
| Gross Margin % | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income (EBIT) | ($16M) | ($18M) | ($12M) | ($13M) | ($5M) | ($13M) | ($11M) | ($13M) |
| Operating Margin % | -2141.6% | — | -1712.1% | -9487.1% | -80.9% | -9653.9% | -14107.9% | -7645.1% |
| Net Income | ($15M) | ($17M) | $10M | ($12M) | ($5M) | ($10M) | ($9M) | ($14M) |
| Net Margin % | -2047.6% | — | 1345.8% | -9210.6% | -74.7% | -7873.1% | -12175.0% | -8096.0% |
| EBITDA | ($15M) | ($18M) | $10M | ($12M) | ($5M) | ($10M) | ($11M) | ($14M) |
| Earnings Per Share (EPS) | $-0.20 | $-0.23 | $0.12 | $-0.17 | $-0.07 | $-0.14 | $-0.13 | $-0.20 |
| Shares Outstanding (M) | 74M | 74M | 82M | 71M | 71M | 71M | 71M | 71M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($55M) | ($38M) | ($56M) | ($46M) | ($55M) | $119M | ($52M) | ($51M) | ($46M) | ($31M) | ($18M) | ($5M) | $0M |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $1M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($55M) | ($38M) | ($56M) | ($46M) | ($57M) | $118M | ($52M) | ($51M) | ($46M) | ($32M) | ($18M) | ($6M) | $0M |
| FCF Margin % | -3460.1% | -528.6% | -9898.8% | -11713.9% | -3769.5% | 56.8% | -411.9% | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($18M) | ($14M) | ($10M) | ($13M) | ($5M) | ($10M) | ($10M) | ($15M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($18M) | ($14M) | ($10M) | ($13M) | ($5M) | ($10M) | ($10M) | ($15M) |
| FCF Margin % | -2400.3% | — | -1449.6% | -9751.5% | -76.1% | -7924.6% | -13197.4% | -8676.9% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $232M | $151M | $92M | $144M | $155M | $195M | $76M | $81M | $48M | $89M | $53M | $70M | $5M |
| Cash & Cash Equivalents | $11M | $13M | $26M | $27M | $45M | $188M | $72M | $42M | $36M | $87M | $52M | $70M | $5M |
| Total Liabilities | $22M | $20M | $24M | $56M | $23M | $15M | $32M | $11M | $9M | $6M | $4M | $2M | $0M |
| Total Debt (Short + Long-Term) | $1M | $1M | $1M | $1M | $1M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Total Shareholders' Equity | $210M | $131M | $68M | $88M | $132M | $180M | $44M | $70M | $39M | $83M | $49M | $68M | $5M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive OVID viewer.
About TickerBase · Data methodology & sources · Privacy · Terms